Table 2.
Comorbidities | Group 1 | Group 2 | Total, N (%) |
---|---|---|---|
Obesity | 2 | 13 | 15 (5.1) |
Asthma | 3 | 9 | 12 (4.1) |
Cardiac diseasea | 5 | 4 | 9 (3) |
Neuro‐developmental diseaseb | 5 | 3 | 8 (2.7) |
Congenital immunodeficiency and using of immunosuppressive drugc | 3 | 4 | 7 (2.4) |
Renal diseased | 2 | 1 | 3 (1.02) |
Hematologic diseasee | 2 | 0 | 2 (0.7) |
Type 1 Diabetes mellitus | 1 | 1 | 2 (0.7) |
Metabolic diseasef | 1 | 1 | 2 (0.7) |
Malignancyg | 1 | 1 | 2 (0.7) |
Hypertension | 1 | 0 | 1 (0.35) |
Celiac disease | 1 | 0 | 1 (0.35) |
Polycystic ovary syndrome | 1 | 0 | 1 (0.35) |
Skinh | 0 | 1 | 1 (0.35) |
Dilated cardiomyopathy (2), atrial septal defect (ASD) (2), ventricular septal defect (VSD), mitral valve regurgitation, pulmonary stenosis, mitral valve prolapse, and asymmetric septal hypertrophy.
Epilepsy (3), cerebral palsy (2), meningomyelocele, muscular dystrophy, and west syndrome.
Severe combined immunodeficiency (SCID), hyperIgE syndrome, inflammatory bowel disease, familial mediterranean fever (FMF), juvenile idiopathic arthritis (JİA), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) with bone marrow transplant.
Bartter syndrome, henoch‐schöenlein purpura, and vesicoureteral reflux.
Thalassemia trait, chronic idiopathic thrombocytopenic purpura.
Pheochromocytoma and Marfan syndrome.
Neuroblastoma, new diagnosis chronic myeloid leukemia.
Psoriasis.